Association of patent ductus arteriosus treatment in extremely low gestational age neonates with two year kidney outcomes: a secondary analysis of the preterm erythropoietin neuroprotection trial (PENUT)
ELGANs receiving treatment for a PDA were less likely to have elevated SBP at two years. Prospective studies are needed to examine the effects of a hemodynamically significant PDA and its management on long-term kidney outcomes.
Authors
- Dinushan C. Kaluarachchi (ORCID: https://orcid.org/0000-0001-8334-6282)
- Paige E. Condit (ORCID: https://orcid.org/0000-0001-7682-7184)
- Shina Menon (ORCID: https://orcid.org/0000-0001-8473-0307)
- Matthew W. Harer (ORCID: https://orcid.org/0000-0001-5493-3269)
- David J. Askenazi (ORCID: https://orcid.org/0000-0002-6840-9887)
- Russell Lee Griffin (ORCID: https://orcid.org/0000-0002-5004-7996)
- Ronnie Guillet (ORCID: https://orcid.org/0000-0003-4394-344X)
Institutions
- University of Wisconsin–Madison (US)
- University of Alabama at Birmingham (US)
- Golisano Children's Hospital (US)
- University of Rochester (US)
- Stanford University (US)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1186/s12882-025-04065-8
- Citations
- 2
- Primary Topic
- Cardiovascular Conditions and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.72